315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
The Readout Loud
00:00
Viking Therapeutics: Advancements in Obesity Drugs
The chapter explores Viking Therapeutics' decision to skip a phase 2B trial and move directly to a phase 3 trial with their injectable obesity drug, along with plans for monthly dosing. The company's impressive growth and potential acquisition in the biopharma industry are also discussed, particularly in the context of their expanding presence in the obesity medication market.
Transcript
Play full episode
